Prasugrel ienopyridine Irreversible inhibition of Renal 7 hrs 7-10 days

Deranged Physiology » Required Reading » Haematology and Oncology

P2Y12 ADP receptor,

A brief summary of antiplatelet agents thus inhibition of

cAMP-dependent

platelet activation

Ticagrelor Nucleoside Reversible inhibition of Biliary 7-8 hrs 3-5 days

(adenosine) P2Y12 ADP receptor,

is is meant as a brief revision antiplatelet drug
analogue thus inhibition of
pharmacology. Antiplatelet agents have come up as a part of
cAMP-dependent
a question on oral anticogulation of AF (estion 4 from
platelet activation
the first paper of 2015), alongside with novel oral
Abciximab Fab fragment Glycoprotein IIb/IIIa Reticulo- 0.5 hr 18-24 hours
anticoagulants.Similarly, estion 13.2 from the first paper
of a human inhibition, thus endothelial
of 2009 asked the candidates to "briefly outline the mode of
monoclonal inhibition of platelet system
action and half life of aspirin, tirofiban and clopidogrel". In
antibody binding to fibrinogen
order to simplify revision, the following table has been
and von Willebrand
constructed.
factor.

Drug Chemical Mechanism Clearance Half- Duration of Tirofiban Small molecule Glycoprotein IIb/IIIa Renal 2 hrs 4-8 hours

properties life effect non-peptide inhibition, thus

Aspirin Salycilate; Irreversible COX-1 Renal 1-2 hrs 7-10 days inhibition of platelet

Weak acid inhibition, thus binding to fibrinogen

decreased production of and von Willebrand

the prothrombotic factor.

thromboxane A2

Clopidogre ienopyridine Irreversible inhibition of 50% renal, 0.5-1 hrs 7-10 days
Previous chapter:
l P2Y12 ADP receptor, 50% biliary
Heparin-Induced
thus inhibition of
rombocytopenia
cAMP-dependent

platelet activation Next chapter: A brief

summary of oral
 anticoagulant agents [Submit a comment or correction]

References

Siller‐Matula, Jolanta M., Julia Krumphuber, and Bernd

Jilma. "Pharmacokinetic, pharmacodynamic and clinical
profile of novel antiplatelet drugs targeting vascular
diseases." British journal of pharmacology 159.3 (2010): 502-
517.

Farid, Nagy A., Atsushi Kurihara, and Steven A. Wrighton.

"Metabolism and disposition of the thienopyridine
antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in
humans." The Journal of Clinical Pharmacology 50.2 (2010):
126-142.

Levine, Glenn N., et al. "Newer pharmacotherapy in patients

undergoing percutaneous coronary interventions: a guide
for pharmacists and other health care
professionals." Pharmacotherapy: The Journal of Human
Pharmacology and Drug Therapy 26.11 (2006): 1537-1556.
© Alex Yartsev
2013-2024